Biopharma Asset Strategies: Buy, Partner, or Develop

Co-authored by Anshul Mangal, President and Jim Watson, Vice President

As leading consultants in the pharma and biotech industry, our experts are regularly discussing portfolio and asset management with investors and company stakeholders. We also sit on various public and private boards and regularly advise biotechs on their short- and long-term drug development strategies, helping to bring countless therapies to market. 

Based on our experiences, we’ve gathered a wealth of lessons and best practices for what makes a program or asset successful. 

In this article published in BioSpace, "When Should Biopharma Companies Buy, Partner or Develop Innovative Assets", our team discusses how to determine the right entry strategy for continued innovation. 

Whether building a proprietary platform, acquiring another company or asset, or partnering with an established entity, it is important to consider resource allocation, risk management, and long-term viability. 

Click here to read the full article published in BioSpace.

About Project Farma

Project Farma, a Precision for Medicine company, specializes in providing comprehensive biomanufacturing strategies and execution services. We have successfully industrialized over 10 commercial cell, gene, and novel therapies, executed 60+ facility builds and capital expansions, and managed $6B+ in technical operations capital investments.

With expertise spanning startups, leading life science corporations, advanced therapy organizations, universities, hospitals, government agencies, and more, our team delivers proven technical operations and manufacturing solutions that shorten time-to-market, helping patients in need.

Visit our website to learn more about Project Farma and how Precision for Medicine’s integrated capabilities — across labs, clinical trials, manufacturing, and data intelligence— can help your organization bring therapies to life.